Becton, Dickinson and Company

Healthcare · Medical - Instruments & Supplies

Overall research band Mixed

Quality Weak

Valuation Mixed

Balance sheet Very weak

Market confirmation Exceptional

One-minute company read

What this report can tell you now

What the company does

Becton, Dickinson and Company (BD) is a global medical technology enterprise headquartered in Franklin Lakes, New Jersey, specializing in the development, manufacturing, and distribution of medical supplies, devices, laboratory equipment, and diagnostic products. Its main offerings include medication management and drug delivery systems such as IV access solutions, syringes, needles, infusion therapy systems, and diabetes management products; diagnostic and research tools for specimen and blood collection, automated culturing, molecular testing, and cell analysis; and specialized surgical and interventional products for hernia repair, biosurgery, infection prevention, and urology. BD serves healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public worldwide, generating revenue through the sale of its diverse portfolio of medical and laboratory products.

The current research profile is Mixed Setup, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC5.1%Model input; read with the evidence status and period context.

Operating margin11.8%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years3.4%Model input; read with the evidence status and period context.

FCF margin12.2%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.